Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.S. FDA Head Says Chinese Heparin Contaminated On Purpose

This article was originally published in PharmAsia News

Executive Summary

The head of the U.S. FDA says the agency suspects the heparin blood thinner supplied by Chinese companies was contaminated intentionally in a case of fraud. Commissioner Andrew von Eschenbach told an audience the heparin at fault for U.S. deaths contained oversulfated chondroitin sulfate, a version of a dietary supplement. "It was apparently done, we suspect, by virtue of economic fraud," he said, without elaboration. Other FDA officials have said it is cheaper to make heparin that way because the contaminate version is chemically similar to heparin's active ingredient, made from pig intestines. (Click here for more - a subscription may be required

You may also be interested in...

International "Comparability" Of Regulatory Standards May Be FDA's Solution To GMP Oversight

FDA may begin to rely on foreign government oversight of manufacturing even if the standards for the overseas regulators do not exactly match those in the U.S

International "Comparability" Of Regulatory Standards May Be FDA's Solution To GMP Oversight

As the agency struggles to adapt to globalization of the pharmaceutical supply chain, exact harmonization of regulatory standards may not be a goal worth pursuing.

China’s State FDA To Implement Electronic Tracking Network To Improve Drug Safety

SHANGHAI - China's State SFDA will implement an electronic ID-based drug-tracking system this year, the drug watchdog announced at a monthly press conference April 8

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts